Categories: Genetic diseases, Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Aspergillosis

MalaCards integrated aliases for Aspergillosis:

Name: Aspergillosis 57 12 75 53 59 55 43 3 44 15 17 72 33
Aspergillosis, Susceptibility to 57 29 13 6 40
Infection Due to Aspergillus 12


Orphanet epidemiological data:

Inheritance: Not applicable; Age of onset: All ages;


Orphanet: 59  
Rare infectious diseases

External Ids:

Disease Ontology 12 DOID:13564
OMIM 57 614079
ICD9CM 35 117.3
MeSH 44 D001228
NCIt 50 C2886
SNOMED-CT 68 65553006
ICD10 33 B44 B44.9
MESH via Orphanet 45 D001228
ICD10 via Orphanet 34 B44.0 B44.1 B44.2 more
UMLS via Orphanet 73 C0004030
Orphanet 59 ORPHA1163
UMLS 72 C0004030

Summaries for Aspergillosis

NIH Rare Diseases : 53 Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue. Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune systems due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. In this condition, the fungus invades and damages tissues in the body. Invasive aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain). Aspergilloma, a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess, is a third kind of aspergillosis. This type of aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells. The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.

MalaCards based summary : Aspergillosis, also known as aspergillosis, susceptibility to, is related to invasive aspergillosis and allergic bronchopulmonary aspergillosis, and has symptoms including fever and pruritus. An important gene associated with Aspergillosis is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Guaifenesin and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and liver, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An opportunistic mycosis that involves a spectrum of diseases of humans and animals caused by members of the genus Aspergillus infecting lungs, brain, kidney, heart, bone, eyes, sinuses, skin and gastrointestinal tract. It is a serious illnesses in people with a weakened immune system.

OMIM : 57 Aspergillus species are ubiquitous in nature and cause a wide spectrum of diseases, including saprophytic colonization of existing cavities (aspergilloma), allergic asthma, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, and disseminated disease associated with high mortality rates in patients with hematologic malignancies and recipients of solid organs and stem cell transplantations. Immunocompetent and nonatopic individuals are relatively resistant to infection, and disease occurs in the setting of host damage. Association of persistent inflammation with intractable infection is common in nonneutropenic patients after hematopoietic stem cell transplantation, as well as in allergic fungal diseases. The pathophysiology underlying Aspergillus infection highlights the bipolar nature of the inflammatory process in infection, in which early inflammation prevents or limits infection, but an uncontrolled response may oppose disease eradication (summary by Cunha et al., 2010). For information on familial occurrence of allergic bronchopulmonary aspergillosis, see 103920. (614079)

MedlinePlus : 43 Aspergillosis is a disease caused by a fungus (or mold) called Aspergillus. The fungus is very common in both indoors and outdoors. Most people breathe in the spores of the fungus every day without being affected. But some people get the disease. It usually occurs in people with lung diseases or weakened immune systems. There are different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA). Symptoms of ABPA include wheezing and coughing. ABPA can affect healthy people but it is most common in people with asthma or cystic fibrosis. Another kind is invasive aspergillosis, which damages tissues in the body. It usually affects the lungs. Sometimes it can also cause infection in other organs and spread throughout the body. It affects people who have immune system problems, such as people who have had a transplant, are taking high doses of steroids, or getting chemotherapy for some cancers. Your doctor might do a variety of tests to make the diagnosis, including a chest x-ray, CT scan of the lungs, and an examination of tissues for signs of the fungus. Treatment is with antifungal drugs. If you have ABPA, you may also take steroids. Centers for Disease Control and Prevention

CDC : 3 Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs.

Wikipedia : 75 Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus... more...

Related Diseases for Aspergillosis

Diseases in the Aspergillosis family:

Invasive Aspergillosis

Diseases related to Aspergillosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 902)
# Related Disease Score Top Affiliating Genes
1 invasive aspergillosis 33.8 TLR9 TLR4 TLR2 SFTPD MBL2 IFNG
2 allergic bronchopulmonary aspergillosis 33.8 SFTPD SFTPA2 MBL2 IL5 IL4 CFTR
3 candidiasis 31.8 MBL2 IL10 IFNG CLEC7A
4 bronchiectasis 31.5 TLR2 MBL2 ELANE CFTR
5 hypereosinophilic syndrome 31.3 IL5 IL4 CCL17
6 hematopoietic stem cell transplantation 31.2 TNF IL10 IFNG CLEC7A
7 cystic fibrosis 31.1 TLR4 SFTPD MBL2 ELANE CFTR
8 eosinophilic pneumonia 31.1 SFTPD IL5 CCL17
9 cryptococcosis 31.0 TLR9 MBL2 IL4 IFNG
10 immune deficiency disease 31.0 TLR9 IL4 IL10
11 ige responsiveness, atopic 31.0 IL5 IL4 IL10 IFNG
12 hyper ige syndrome 30.9 TLR2 IL4 IFNG
13 graft-versus-host disease 30.9 TNF IL10 IFNG
14 coccidioidomycosis 30.8 TLR4 MBL2 IL10 CLEC7A
15 allergic rhinitis 30.7 IL5 IL4 IL10 IFNG
16 pulmonary eosinophilia 30.7 SFTPD IL5 IL4 CCL17
17 conjunctivitis 30.6 IL5 IL4 IFNG
18 osteomyelitis 30.6 TNF IL10 IFNG
19 allergic asthma 30.6 IL5 IL4 IL10 IFNG CCL17
20 endocarditis 30.6 TNF TLR2 IL10
21 pneumocystosis 30.6 TNF SFTPD CLEC7A
22 chronic graft versus host disease 30.6 TNF IL10 IFNG
23 paranasal sinus disease 30.5 IL5 IL4 IL10 IFNG
24 bacterial pneumonia 30.5 TLR9 TLR4 SFTPD ELANE
25 allergic hypersensitivity disease 30.5 TLR9 IL5 IL4 IL10 IFNG CCL17
26 septic arthritis 30.5 TLR9 TLR4 TLR2
27 acute graft versus host disease 30.5 TNF IL4 IL10 IFNG
28 tetanus 30.4 IL5 IL4 IL10 IFNG
29 acute respiratory distress syndrome 30.4 TNF SFTPD ELANE
30 granulomatosis with polyangiitis 30.3 TLR9 TLR2 ELANE
31 idiopathic interstitial pneumonia 30.3 TLR9 SFTPD SFTPA2 IL4 IFNG ELANE
32 keratitis, hereditary 30.3 TLR9 TLR4 TLR2
33 food allergy 30.3 IL5 IL4 IL10 IFNG
34 bronchiolitis obliterans 30.3 TNF IL10 IFNG
35 folliculitis 30.3 IL5 IL4 IFNG
36 pulmonary disease, chronic obstructive 30.3 TNF TLR2 SFTPD ELANE CFTR
37 pulmonary sarcoidosis 30.3 TNF SFTPD IFNG
38 bronchitis 30.2 TNF IL5 ELANE CFTR
39 penicilliosis 30.2 TNF TLR4 TLR2
40 pyelonephritis 30.2 TNF TLR4 IL10
41 neuritis 30.2 TNF IL4 IFNG
42 fungal keratitis 30.1 TLR4 TLR2 CLEC7A CD209
43 peritonitis 30.1 TNF TLR2 IL10
44 dermatitis 30.1 TLR9 IL5 IL4 IFNG CCL17
45 stevens-johnson syndrome/toxic epidermal necrolysis 30.1 TLR9 IL5 IFNG CCL17
46 uveitis 30.1 TNF IL4 IL10 IFNG
47 toxic shock syndrome 30.0 TNF TLR4 TLR2 IL4 IL10 IFNG
48 cutaneous t cell lymphoma 30.0 IL4 IFNG CCL17
49 systemic scleroderma 29.9 TLR9 SFTPD IFNG
50 churg-strauss syndrome 29.9 TNF IL5 IL10 CCL17

Comorbidity relations with Aspergillosis via Phenotypic Disease Network (PDN):

Bronchiectasis Bronchitis
Deficiency Anemia Heart Disease
Postinflammatory Pulmonary Fibrosis Respiratory Failure

Graphical network of the top 20 diseases related to Aspergillosis:

Diseases related to Aspergillosis

Symptoms & Phenotypes for Aspergillosis

Clinical features from OMIM:


UMLS symptoms related to Aspergillosis:

fever, pruritus

MGI Mouse Phenotypes related to Aspergillosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 CCL17 CFTR CLEC7A ELANE IFNG IL10
2 immune system MP:0005387 10.22 CCL17 CFTR CLEC7A ELANE IFNG IL10
3 homeostasis/metabolism MP:0005376 10.21 CFTR CLEC7A ELANE IFNG IL10 IL4
4 digestive/alimentary MP:0005381 10.13 CFTR CLEC7A IFNG IL10 IL4 IL5
5 liver/biliary system MP:0005370 9.86 CFTR IFNG IL10 IL4 IL5 TLR2
6 neoplasm MP:0002006 9.76 ELANE IFNG IL10 IL5 TLR2 TLR3
7 reproductive system MP:0005389 9.61 CFTR IFNG IL10 IL4 IL5 PTX3
8 respiratory system MP:0005388 9.4 CFTR CLEC7A IFNG IL10 IL4 IL5

Drugs & Therapeutics for Aspergillosis

Drugs for Aspergillosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
Omalizumab Approved, Investigational Phase 4 242138-07-4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
12 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
13 Antitussive Agents Phase 4
14 Micronutrients Phase 4
15 Trace Elements Phase 4
16 Vitamin D2 Phase 4
17 Vitamins Phase 4
18 Ergocalciferols Phase 4
19 Nutrients Phase 4
20 Calciferol Phase 4
21 Calcium, Dietary Phase 4
22 Bone Density Conservation Agents Phase 4
23 Immunoglobulin G Phase 4
24 Immunologic Factors Phase 4
25 Liposomal amphotericin B Phase 4
26 Anti-Bacterial Agents Phase 4
Hydroxyitraconazole Phase 4
28 Anti-Allergic Agents Phase 4
29 Respiratory System Agents Phase 4
30 Immunoglobulin E Phase 4
31 Antibodies Phase 4
32 Immunoglobulins Phase 4
33 Anti-Asthmatic Agents Phase 4
34 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
35 glucocorticoids Phase 4
36 Pharmaceutical Solutions Phase 4
Midazolam Approved, Illicit Phase 2, Phase 3 59467-70-8 4192
deoxycholic acid Approved Phase 3 83-44-3 222528
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
Natamycin Approved Phase 3 7681-93-8 5281099
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
Fluticasone Approved, Experimental Phase 2, Phase 3 90566-53-3 62924
Pirfenidone Approved, Investigational Phase 2, Phase 3 53179-13-8 40632
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
48 Ophthalmic Solutions Phase 2, Phase 3
49 Amphotericin B, deoxycholate drug combination Phase 3
50 Cholagogues and Choleretics Phase 3

Interventional clinical trials:

(show top 50) (show all 211)
# Name Status NCT ID Phase Drugs
1 Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Unknown status NCT00986713 Phase 4 Amphotericin B
2 Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD: a Multi-center Prospective,Open Cohort Study (VIA-COPD) Unknown status NCT02234739 Phase 4 Voriconazole
3 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS Completed NCT01259336 Phase 4 Itraconazole;treatment in cavitary pulmonary aspergillosis
5 A Phase 4, Open Label Study To Assess The Bronchopulmonary Pharmacokinetics Of Anidulafungin And Voriconazole Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
6 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
7 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
8 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
9 Pharmacokinetics of Voriconazole in Obese Subjects Completed NCT01030653 Phase 4 Voriconazole low dose;Voriconazole high dose
10 Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
11 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
12 Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy Completed NCT01539330 Phase 4 Voriconazole
13 A Phase iv, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically Ill Patients Recruiting NCT03378479 Phase 4 SOC +Posaconazole 18 MG/ML (milligram/milliliter)
14 A Randomized Controlled Trial of the Effect of Cytochrome P450 2C19 Genotype-Specific Dosing Plus TDM vs. TDM Alone on Reaching Therapeutic Voriconazole Blood Levels Recruiting NCT03731169 Phase 4 Standard of Care
15 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Not yet recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
16 Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis- A Proof of Concept Study Not yet recruiting NCT03737617 Phase 4 Cuvitru 20 % Injectable Solution
17 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment) Terminated NCT02646774 Phase 4 Micafungin
18 An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA) Terminated NCT00787917 Phase 4 Omalizumab;Placebo;Itraconazole
19 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
20 Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
21 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
22 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
23 A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
24 Effectiveness of Posaconazole as Salvage Treatment After 2 Weeks of Preemptive Antifungal Treatment Withdrawn NCT02020213 Phase 4 Posaconazole
25 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study Unknown status NCT01125644 Phase 3 SPK-843
26 Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis: a Prospective Randomized Double Masked Clinical Trial Unknown status NCT03230058 Phase 2, Phase 3 Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
27 An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis. Completed NCT00037206 Phase 2, Phase 3 Anidulafungin, VER002
28 Randomized Controlled Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Completed NCT00974766 Phase 2, Phase 3 Glucocorticoids;Glucocorticoids
29 A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections Completed NCT00717860 Phase 3 caspofungin acetate;Comparator: Micafungin sodium
30 A Multicentre Randomised Controlled Trial Comparing the Current Standard Diagnostic Strategy for Invasive Aspergillosis to the New Diagnostic Strategy for Invasive Aspergillosis in High-Risk Haematology Patients in Order to Determine Which Strategy Results in the Lower Rates of Use of Empiric Antifungal Therapy Completed NCT00163722 Phase 3
31 An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients Completed NCT00003031 Phase 3 amphotericin B deoxycholate;voriconazole
32 Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi Completed NCT00634049 Phase 3 isavuconazole
33 A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection Completed NCT02180165 Phase 3 Posaconazole;Voriconazole
34 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
35 A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Completed NCT01857479 Phase 2, Phase 3 Inhaled budesonide;Inhaled amphotericin
36 A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma Completed NCT03133299 Phase 2, Phase 3 Glucocorticoids;Vitamin D
37 Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo for the Prophylaxis of Invasive Pulmonary Aspergillosis in Haematological Patients With Prolonged Neutropenia. A Randomized Clinical Trial. Completed NCT00263315 Phase 2, Phase 3 nebulised liposomal amphotericin B
38 A Randomized Controlled Trial of Voriconazole in Allergic Bronchopulmonary Aspergillosis Completed NCT01621321 Phase 2, Phase 3 Prednisolone;Voriconazole
39 A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi. Completed NCT00412893 Phase 3 Isavuconazole;Voriconazole
40 Using Serum Galactomannan Levels in a Prospective, Randomised, Non-blinded Trial to Guide Early Anti-fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis. Completed NCT00361517 Phase 3 Amphotericin-B deoxycholate
41 Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Completed NCT01321827 Phase 2, Phase 3 Glucocorticoids;Itraconazole
42 A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis Completed NCT00531479 Phase 3 voriconazole;anidulafungin;voriconazole
43 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001810 Phase 3 Voriconazole
44 A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 Versus Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoetic Stem Cell Transplant Completed NCT00001937 Phase 3 FK463;Fluconazole
45 A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection. Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
46 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001757 Phase 3 Voriconazole
47 Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections Completed NCT00034658 Phase 3 Posaconazole
48 Mycotic Ulcer Treatment Trial Completed NCT00996736 Phase 3 Natamycin;Voriconazole
49 Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections Completed NCT00034632 Phase 3 Posaconazole oral suspension
50 An Open Label, Non-Comparative, Multi-Center Phase III Trial of the Efficacy, Safety, and Toleration of Extended Voriconazole in the Treatment of Invasive Fungal Infections Completed NCT00001940 Phase 3 Voriconazole

Search NIH Clinical Center for Aspergillosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Caspofungin acetate
Miconazole Nitrate

Cochrane evidence based reviews: aspergillosis

Genetic Tests for Aspergillosis

Genetic tests related to Aspergillosis:

# Genetic test Affiliating Genes
1 Aspergillosis, Susceptibility to 29 CLEC1A CLEC7A

Anatomical Context for Aspergillosis

MalaCards organs/tissues related to Aspergillosis:

Lung, Testes, Liver, Bone, Myeloid, Bone Marrow, Brain

Publications for Aspergillosis

Articles related to Aspergillosis:

(show top 50) (show all 12499)
# Title Authors PMID Year
Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. 38 8 71
20807886 2010
Recognition of DHN-melanin by a C-type lectin receptor is required for immunity to Aspergillus. 8 71
29489751 2018
Toll-like receptor 4 polymorphisms and aspergillosis. 9 38 8
19196681 2009
Toll-like receptor 4 polymorphisms and aspergillosis. 9 38 8
19202579 2009
Toll-like receptor 4 polymorphisms and aspergillosis. 9 38 8
19202580 2009
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. 9 38 8
18946062 2008
Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. 9 38 8
18275280 2008
Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. 38 8
16247433 2005
Copper Utilization, Regulation, and Acquisition by Aspergillus fumigatus. 38 17
31018527 2019
Evaluation of Aspergillus IgG, IgM antibody for diagnosing in chronic pulmonary aspergillosis: A prospective study from a single center in China. 38 17
31008929 2019
Fungal diseases at the medical front door. 38 17
30860923 2019
Human dectin-1 deficiency and mucocutaneous fungal infections. 71
19864674 2009
TLR polymorphisms and the risk of invasive fungal infections. 8
18946070 2008
Identification of a human homologue of the dendritic cell-associated C-type lectin-1, dectin-1. 8
11470510 2001
Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. 9 38
20413160 2010
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. 9 38
19827955 2009
Identification of Aspergillus species in oral tissue samples of patients with hematologic malignancies by in situ hybridization: a preliminary report. 9 38
18718399 2008
Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. 9 38
17335555 2007
Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. 9 38
17311505 2007
Chemokines in allergic aspergillosis--from animal models to human lung diseases. 9 38
17168792 2006
[Clinical analysis of chronic pulmonary aspergillosis and discovery of an elastase inhibitor]. 9 38
16940951 2006
[A case of idiopathic pulmonary upper lobe fibrosis complicated by invasive pulmonary aspergillosis]. 9 38
12772600 2003
[Successful treatment of invasive pulmonary aspergillosis with G-CSF and M-CSF during long-term bone marrow suppression in hypoplastic leukemia]. 9 38
11979751 2002
Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. 9 38
11474427 2001
Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus. 9 38
11500084 2001
A 1.1-kb duplication in the p67-phox gene causes chronic granulomatous disease. 9 38
11499676 2001
Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis. 9 38
11254642 2001
Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. 9 38
10878372 2000
[Aspergillosis: Mechanisms of pathogenicity implicated and approach to laboratory diagnosis.]. 9 38
17655396 1998
Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils. 9 38
9367408 1997
Polymerase chain reaction amplification of Asp f I and alkaline protease genes from fungus balls: clinical application in pulmonary aspergillosis. 9 38
9058095 1997
[Invasive pulmonary aspergillosis in a patient with acute leukemia--the role of neutrophil elastase in in cavity formation]. 9 38
8691669 1996
[Protective effect of human macrophage colony-stimulating factor on fungal infection (2). In vitro effect of human macrophage colony-stimulating factor on systemic aspergillosis and in vitro effect on the activities of macrophage]. 9 38
7602192 1995
Western blot detection of IgG anti-Aspergillus fumigatus elastase in sera of patients with aspergillosis. 9 38
7965494 1994
Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis. 9 38
1452348 1992
Control of proven pulmonary and suspected CNS aspergillus infection with itraconazole in a patient with chronic granulomatous disease. 9 38
1655460 1991
[Aspergillus mastoiditis in infected granulomatosis--a case report]. 9 38
2165779 1990
Differential requirements of protein geranylgeranylation for the virulence of human pathogenic fungi. 38
31131706 2019
The mitochondrial thiamine pyrophosphate transporter TptA promotes adaptation to low iron conditions and virulence in fungal pathogen Aspergillus fumigatus. 38
30880633 2019
Invasive tracheal aspergillosis after chemoradiotherapy treatment. 38
31406579 2019
Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab. 38
31346471 2019
Primary intestinal aspergillosis resulting in acute intestinal volvulus after autologous stem cell transplantation in a patient with relapsed non-Hodgkin lymphoma: report on a rare infectious complication and a review of the literature. 38
30238855 2019
Development of a new stability indicating method for the simultaneous separation of voriconazole from its impurities along with sodium benzoate used as a preservative in a powder for oral suspension. 38
31257019 2019
Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. 38
31402007 2019
Disseminated cerebral aspergillosis complicated by thrombotic microangiopathy. 38
31334000 2019
A unique case of hydropneumothorax in allergic bronchopulmonary aspergillosis. 38
31338287 2019
Cor pulmonale complicating chronic pulmonary aspergillosis with fatal consequences: Experience from Uganda. 38
31333999 2019
Internal Carotid Artery Bleed: A Rare Complication of Invasive Sphenoidal Aspergillosis. 38
31203084 2019
A murine model of cutaneous aspergillosis for evaluation of biomaterials-based local delivery therapies. 38
30882993 2019
Higher frequency of false-positive serum galactomannan tests among older subjects and the association with elevated serum immunoglobulin G levels. 38
31165504 2019

Variations for Aspergillosis

ClinVar genetic disease variations for Aspergillosis:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CLEC1A NM_001297750.2(CLEC1A): c.-286G> C single nucleotide variant risk factor 12:10251445-10251445 12:10098846-10098846
2 CLEC7A NM_197947.2(CLEC7A): c.714T> G (p.Tyr238Ter) single nucleotide variant Benign rs16910526 12:10271087-10271087 12:10118488-10118488

Expression for Aspergillosis

Search GEO for disease gene expression data for Aspergillosis.

Pathways for Aspergillosis

Pathways related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.68 TNF TLR4 TLR2 IL5 IL4 IL10
Show member pathways
8 12.63 TNF TLR9 TLR3 TLR2 IL4 IL10
Show member pathways
12.61 TNF IL5 IL4 IL10 IFNG
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.3 TNF IL5 IL4 IL10 IFNG
Show member pathways
12.27 TLR9 TLR4 TLR3 TLR2 CCL3 CCL17
Show member pathways
12.27 TNF TLR9 IL10 CLEC7A CD209 CCL17
Show member pathways
Show member pathways
12.15 IL5 IL4 IL10 IFNG CCL3 CCL17
Show member pathways
Show member pathways
12.13 TLR9 TLR4 TLR3 TLR2 IL5
23 12.07 TNF IL5 IL4 IL10 IFNG CD209
24 12.06 TNF TLR4 IL4 IFNG
25 12.03 TNF TLR4 TLR2 IL10 IFNG
26 11.98 TNF TLR4 TLR2 IFNG CCL3
Show member pathways
11.98 TNF TLR9 TLR4 TLR3 TLR2 IL10
28 11.94 TLR9 TLR4 TLR3 TLR2 CLEC7A
29 11.88 TNF IL5 IL4
30 11.86 TNF IL5 IL4 IL10 IFNG CCL3
31 11.85 TNF TLR4 SFTPA2 IL10
Show member pathways
11.85 TNF IL5 IL4 IFNG
33 11.81 TNF TLR9 IL10 IFNG CD209
34 11.81 TNF TLR9 TLR4 TLR2 IL10 IFNG
35 11.8 TLR4 IFNG CCL3
36 11.8 IL5 IL4 IFNG
37 11.76 IL5 IL4 IL10 CCL17
38 11.73 TNF IL4 IL10 IFNG CCL3 CCL17
39 11.65 TNF IL4 IL10 CCL3
40 11.64 TNF SFTPA2 PTX3 IL5 IL4 CCL3
41 11.63 TNF TLR4 TLR2 IFNG
42 11.62 TNF TLR4 TLR2
43 11.57 IL5 IL4 IL10 IFNG CCL17
44 11.5 TNF TLR9 IL10 IFNG
Show member pathways
46 11.43 TNF IL5 IL4 IFNG
47 11.42 TNF TLR9 TLR4 TLR2 IL10 IFNG
48 11.4 TNF TLR4 IL10
49 11.38 IL5 IL4 IFNG
50 11.32 TNF IL5 IL4 IL10 IFNG

GO Terms for Aspergillosis

Cellular components related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF TLR9 SFTPD SFTPA2 PTX3 MBL2
2 cell surface GO:0009986 9.76 TNF TLR4 TLR3 TLR2 MBL2 ELANE
3 endosome membrane GO:0010008 9.56 TLR9 TLR4 TLR3 CFTR
4 collagen trimer GO:0005581 9.5 SFTPD SFTPA2 MBL2
5 extracellular space GO:0005615 9.44 TNF TLR3 SFTPD SFTPA2 PTX3 MBL2
6 endolysosome membrane GO:0036020 9.37 TLR9 TLR3

Biological processes related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of JNK cascade GO:0046330 9.97 TNF TLR9 TLR4 TLR3
2 positive regulation of interleukin-6 production GO:0032755 9.97 TNF TLR9 TLR4 TLR3 TLR2
3 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.96 TNF TLR9 TLR4 TLR3
4 positive regulation of tumor necrosis factor production GO:0032760 9.95 TLR9 TLR4 TLR3 TLR2 CCL3
5 positive regulation of nitric oxide biosynthetic process GO:0045429 9.94 TNF TLR4 PTX3 IFNG
6 positive regulation of B cell proliferation GO:0030890 9.93 TLR9 TLR4 IL5 IL4
7 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.93 TNF TLR9 TLR4 TLR3 TLR2
8 lipopolysaccharide-mediated signaling pathway GO:0031663 9.92 TNF TLR4 TLR2 CCL3
9 defense response to bacterium GO:0042742 9.92 TNF TLR9 TLR4 TLR3 SFTPD MBL2
10 positive regulation of inflammatory response GO:0050729 9.91 TNF TLR9 TLR4 TLR3 TLR2 CCL3
11 apoptotic signaling pathway GO:0097190 9.9 TNF TLR4 TLR3
12 negative regulation of interleukin-6 production GO:0032715 9.9 TNF TLR9 TLR4 IL10
13 positive regulation of interferon-beta production GO:0032728 9.89 TLR9 TLR4 TLR3 TLR2
14 extrinsic apoptotic signaling pathway GO:0097191 9.88 TNF TLR3 IFNG
15 negative regulation of osteoclast differentiation GO:0045671 9.88 TLR4 TLR3 IL4 CCL3
16 positive regulation of phagocytosis GO:0050766 9.88 TNF SFTPD SFTPA2 PTX3 MBL2
17 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.86 TLR9 TLR4 TLR2
18 positive regulation of interleukin-10 production GO:0032733 9.85 TLR9 TLR4 TLR2
19 immune response GO:0006955 9.85 TNF TLR9 TLR4 TLR2 IL5 IL4
20 microglial cell activation GO:0001774 9.84 TNF TLR3 TLR2
21 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.83 TLR9 TLR4 TLR2
22 negative regulation of growth of symbiont in host GO:0044130 9.83 TNF MBL2 IL10 ELANE
23 response to molecule of bacterial origin GO:0002237 9.82 TLR9 TLR2 IL10
24 positive regulation of interferon-beta biosynthetic process GO:0045359 9.81 TLR9 TLR4 TLR3
25 I-kappaB phosphorylation GO:0007252 9.81 TLR9 TLR4 TLR3 TLR2
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.8 TLR4 IL4 IL10
27 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.8 TNF TLR9 TLR4 ELANE
28 positive regulation of interleukin-8 production GO:0032757 9.8 TNF TLR9 TLR4 TLR3 TLR2
29 positive regulation of interleukin-12 production GO:0032735 9.77 TLR9 TLR4 TLR3 TLR2 IFNG
30 positive regulation of toll-like receptor signaling pathway GO:0034123 9.76 TLR9 TLR3 TLR2
31 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.74 TLR9 TLR3
32 macrophage chemotaxis GO:0048246 9.74 SFTPD CCL3
33 positive regulation of podosome assembly GO:0071803 9.74 TNF IL5
34 negative regulation of interleukin-17 production GO:0032700 9.74 TLR4 IFNG
35 cell activation GO:0001775 9.74 TLR2 CCL3
36 surfactant homeostasis GO:0043129 9.73 SFTPD SFTPA2
37 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.73 TLR4 TLR3
38 cellular response to lipoteichoic acid GO:0071223 9.73 TLR4 TLR2
39 opsonization GO:0008228 9.73 PTX3 MBL2
40 positive regulation of chemokine biosynthetic process GO:0045080 9.73 TNF TLR3
41 endothelial cell apoptotic process GO:0072577 9.73 TNF IL10
42 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.72 TLR4 TLR3
43 negative regulation of interleukin-8 production GO:0032717 9.72 TLR9 IL10
44 negative regulation of cytokine secretion involved in immune response GO:0002740 9.72 TNF IL10
45 necroptotic signaling pathway GO:0097527 9.71 TNF TLR3
46 tumor necrosis factor production GO:0032640 9.71 TLR9 TLR2
47 positive regulation of interleukin-18 production GO:0032741 9.71 TLR9 TLR2
48 type 2 immune response GO:0042092 9.7 IL4 IL10
49 response to yeast GO:0001878 9.7 PTX3 ELANE
50 regulation of isotype switching GO:0045191 9.7 IL4 IL10

Molecular functions related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 TNF TLR4 TLR3 TLR2 SFTPD PTX3
2 transmembrane signaling receptor activity GO:0004888 9.73 TLR9 TLR4 TLR3 CLEC1A
3 virion binding GO:0046790 9.46 PTX3 CD209
4 lipopolysaccharide binding GO:0001530 9.46 TLR4 TLR2 SFTPD SFTPA2
5 signaling pattern recognition receptor activity GO:0008329 9.43 TLR9 TLR2 CLEC7A
6 carbohydrate binding GO:0030246 9.43 SFTPD SFTPA2 MBL2 CLEC7A CLEC1A CD209
7 lipopolysaccharide receptor activity GO:0001875 9.32 TLR4 TLR2
8 cytokine activity GO:0005125 9.17 TNF IL5 IL4 IL10 IFNG CCL3
9 protein binding GO:0005515 10.33 TNF TLR4 TLR3 TLR2 SFTPD PTX3

Sources for Aspergillosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....